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The use of a concentrate containing milk immunoglobulins prepared from rotavirus-
hyperimmunized cows (neutralization titer, 1:6,000 for a 10070 solution) to treat infants
hospitalized for acute rotavirus gastroenteritis resulted in a significant (P = .(08) reduc-
tion in the duration of excretion of virus. Stool samples from treated infants showed the
presence of bovine milk immunoglobulins in 47% of cases and of neutralizing activity
in 43% (mean neutralization titer, 1:48); stool samples from control infants showed neu-
tralizing activities in only 30J0 of cases (neutralization titers, <1:20). Immunoelectropho-
resis of stool extracts revealed fragment A, a bovine analogue of Ftab'), or Fab, as the
major product of in vitro and in vivo digestion of the immunoglobulins. Cessation of
excretion of virus correlated with the appearance of neutralizing activities in 19 of 25
infants. Only concentrate-treated infants with high neutralizing activity in stools showed
a statistically significant reduction in duration of excretion of virus; this duration in
concentrate-treated infants with low neutralizing activity was comparable with controls.
Rotaviruses were first recognized in 1973 as a cause
of nonbacterial infectious gastroenteritis in infants
[1]. Epidemiological studies have shown that rota-
viruses are found in 400,10-500,10 of infants with gas-
troenteritis who were admitted to hospitals during
the cold season [2-4]. The highest incidence of
rotavirus infection has been observed in children six
months to two years of age [2, 3, 5].
Active immunization as an appropriate im-
munoprophylaxis against infection is the subject of
intensive research [6-8], and encouraging results have
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been obtained with a bovine rotavirus vaccine [9, 10].
Nevertheless, because of problems arising from the
practicability of actively immunizing young infants
and from treating diarrheal disease caused by rotavi-
rus infections in hospitalized infants, passive immu-
nization also remains of major importance.
Animal studies [11-17] suggest that orally ad-
ministering virus-neutralizing milk and blood serum
antibodies provides local, passive immune protec-
tion against experimental rotavirus infection. Clini-
cal studies to investigate whether breast-fed infants
suffer less diarrhea than do formula-fed infants have
given contradictory results, as reviewed by Cushing
and Anderson [18]. Both breast-fed and bottle-fed
infants develop rotavirus diarrhea [19]. In some
studies [20, 21j, breast-fed infants were observed to
excrete rotavirus significantly less frequently and in
lower titers than did formula-fed infants. In a lon-
gitudinal study in northern Canada [22], however,
breast-feeding appeared to offer no protection from
either rotavirus infection or symptomatic illness.
Two studies on passive immune prophylaxis of
rotavirus gastroenteritis in human infants have been
carried out. Barnes et al. [23] reported favorable
results in a prevention trial with gamma-globulin
from human blood serum orally administered to in-
fants of low birth weight. Ebina et al. [24, 25] fed
lyophilized, skimmed colostral milk from rotavirus-
immunized cows to infants. Although the number
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of infants tested was small, prevention of rotavirus
gastroenteritis seemed to be possible, although the
treatment was unsuccessful.
In earlier publications [26, 27] we described the
preparation of a concentrate of immunoglobulins
isolated from the milk of Escherichia coli-im-
munized milking cows and the promising use of this
concentrate for treating infantile gastroenteritis
caused by enteropathogenic E. coli. Here we report
on a bovine milk concentrate containing antibody
to human rotavirus and on its efficiency in treating
infantile rotavirus gastroenteritis.
Subjects and Methods
Milk immunoglobulin concentrate. The prepa-
ration and antiviral activity of concentrate samples
A, B, and C is described in detail elsewhere [28]. In
brief, the concentrate was prepared from cow's milk
by removing milk fat, casein, lactose, and mineral
salts. The milk was then sterile filtered, and the
resulting whey protein solution was freeze dried.
Concentrate A (neutralization titer of 10070 solution,
1:330) was isolated from mixed colostral milk (first
and second milking after calving) from at least five
nonimmunized cows. Concentrate B (neutralization
titer of 10070 solution, 1:1,100) was isolated from the
mixed milk of 40 lactation days after calving from
rotavirus-hyperimmunized cows. Concentrate C
(neutralization titer of 10070 solution, 1:6,000) was
prepared from the mixed milk of only 10 lactation
days after calving from at least four rotavirus-
hyperimmunized cows.
Stool samples. Stools were frozen within 2 hr af-
ter defecation and kept at - 20 C. Extracts werepre-
pared by using 10 ml of ice-cold PBS (pH 7.2)1gof
stool. Stool extracts were clarified by centrifugation
(10,000 g for 20 min at 0 C).
Neutralization test. A series of twofold dilutions,
starting with a 1:5 dilution, of stool extracts (10070
stool suspension in PBS), was used for neutraliza-
tion tests, according to Gerna et al. [29]. Bovine
rotavirus vioos [30, 31], human rotavirus Wa (sero-
type 1) [32], and simian rotavirus SA-ll [32] were
used to measure rotavirus-neutralizing activity.
In vitro proteolysis. At enzyme: substrate ratios
of 1:150, 1:30, and 1:6, solutions of 1mg of concen-
trate/ml were subjected to in vitro proteolysis by pep-
sin (Sigma, St. Louis) at pH 2 (0. 05 MKCl and 0.001
M HCl buffer), pH 3 (0.05 M glycine and 0.001 M
HCl buffer), and pH 4 (0.07 M sodium acetate) and
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by trypsin (Serva, Heidelberg, FRO) at pH 8.0 (0.05
MTris-HCI and 0.01 MCaClz) for 2 hr at 37 C. Pep-
sin was inactivated by using 10070 NazC03 to raise
the pH to 8.0. Trypsin was inactivated by adding soy-
bean trypsin inhibitor (Serva).
Immunodiffusion techniques. Double immuno-
diffusion tests were performed according to the
methods of Ouchterlony [33]. Immunoelectropho-
resiswas carried out as described by Scheidegger [34].
Agarose gels for both techniques werepoured on Gel-
bond Film (LKB-Produkter AB, Bromma, Sweden).
Freeze-dried rabbit antibody to bovine IgOI (gift
from J. J. Pahud, Nestle, Lausanne) was used in a
1:5 dilution for both techniques. Fecal extracts were
used undiluted.
Clinical studies. One hundred sixty-four infants
up to two years of age who had been admitted to
the University Children's Hospital at Bochum with
acute gastroenteritis were included in this study. All
infants had been fed a commercial milk formula be-
fore the onset of the disease.
To detect the causative agents of gastroenteritis
(rotavirus, enteropathogenic bacteria), we took two
stool samples as soon as possible after hospital ad-
mission and before treatment was started. Infants
who were positive for rotavirus and negative for en-
teropathogenic bacteria in stools and for whom pa-
rental written, informed consent was obtained were
included in the treatment group; untreated infants
hospitalized during the same period who were posi-
tive for rotavirus and negative for enteropathogenic
bacteria in stools were included in the control group.
The assignment of infants to either the treatment or
control group depended only on whether parenteral
consent could be obtained before or immediately af-
ter two stools were passed. Sometimes the purpose
and conditions of the study could not be explained
to the parents in time, and some parents were op-
posed to any experimental treatment.
In both groups, stools were examined daily for
rotavirus up to the 12th day after admission or until
at least two consecutive negative samples were de-
tected in the same patient. Only those infants with
two consecutive stool samples positive for rotavirus
after hospitalization were included in the study.
Diarrhea was clinically defined as the passing of
liquid or watery stools and was linked with failure
to thrive, loss of weight, and, possibly, vomiting.
Except for the administration of concentrate,
treatment of diarrhea was identical in both groups
and consisted of oral or parenteral rehydration, a di-
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Figure 1. In vitro digestion of the milk immunoglobu-
lin concentrate. The concentrate was digested with tryp-
sin at pH 8 (.) and with pepsin at pH 2 (.A.), 3 (.), and
4 (.) at the indicated enzyme:substrate ratio. The per-
centage of neutralizing activity of the digested concentrate
(mean of triplicate determinations) is plotted on the or-
dinate.
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kit (Rotazymee; Abbott, Diagnostic Products, Wies-
baden, FRO) was used to detect rotavirus. Indica-
tions from the supplier that 5 x 106 rotavirus
particles/ml could be detected were confirmed ex-
perimentally. Furthermore, we determined that in a
range from 5 x 106 to 5 X 108 particles/ml, the op-
tical density read in the ELISA was proportional to
the particle concentration.
To exclude false-negative results due to the coat-
ing of rotavirus particles with bovine antibodies, we
independently tested stool samples taken in the crit-
ical transition period from positive to negative
ELISA for the presence of rotaviruses by RNA gel
electrophoresis or by electron microscopy or byboth
techniques.
Results
In vitroproteolysis. Fifty percent of the antiviral
activity of the concentrates was recovered after ex-
posing them to pepsin at an enzyme:substrate ratio
of 1:150 at pH 4. Thirty percent recovery was ob-
served at a ratio of 1:30. About 20010 of the activity
was recovered at pH 3, with ratios of 1:150and 1:30.
No activity was recovered after exposing the concen-
trates to pepsin at pH 2 (figure 1).Trypsin had nearly
no effect on the biologic activity at an en-
zyme:substrate ratio of 1:150 but reduced the activ-
ity to 30070 and 200/0 at higher enzyme:substrate ra-
tios (figure 1). Fragment A, a bovine analogue of
C.
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Figure 2. Immunoelectrophoresis of in vitro digestion
of the milk immunoglobulin concentrate. a, Control con-
centrate; b, concentrate digested with pepsin (l :150) at pH
4; c, concentrate digested with pepsin (l :150) at pH 3; d,
concentrate digested with pepsin (l :30) at pH 3, A, frag-
ment A; and arrowhead, position of center well. The an-
ode is on the left.
etary regimen with cooked-carrot preparations on
the first day, and a stepwise reintroduction of a com-
mercial infant formula. In the treatment group. the
concentrate containing antibody to rotavirus (A, B,
or C) was added to the indicated dietary regimen at
a daily dosage of 2 g of concentrate/kg of body
weight per day for five days. The administration of
the concentrate was distributed equally over all meals
and started, on average, on the second day of hospi-
talization. Infants were not treated on the first day
of hospitalization because we were concerned that
the initial detection of rotavirus might be masked
by coating the rotavirus particles with bovine anti-
bodies to rotavirus. Further, it took some time to
obtain parental consent.
Detecting rotavirus. A commercial ELISA test
Bovine Milk Antibodies to Rotavirus
F(ab')2 or Fab [35, 36] and intact IgG were revealed
by immunoelectrophoresis of the concentrates after
mild pepsin digestion. Fifty percent of the antiviral
activity survived these conditions (figure 2b). Only
fragment A was detected after pepsin treatment,
which reduced the neutralizing activity to 25% or
15010 (figure 2, c and d).
In vivo proteolysis. A dosage of 2 g of concen-
trate B/kg of body weight per day was given to in-
fants for five days. About half of the stool samples
from concentrate-treated infants contained bovine
milk antibodies exhibiting complete or partial iden-
tity with native bovine milk immunoglobulins in the
Ouchterlony test (figure 3). No bovine immunoglob-
ulins were detected in the stools of control infants.
Immunoelectrophoresis revealed intact IgGI, frag-
rnent A (bovine analogue of Ftab'), or Fab [35, 36]),
fragment B (bovine analogue of Fc [35, 36]), and
fragment C (bovine analogue of Fc' [35, 36]). The
patterns varied for different infants (figure 4).
Antiviral activity. Daily stool samples weretaken
from concentrate-treated and control infants after
hospitalization for rotavirus gastroenteritis. Tworan-
dom stool samples from each of 55 control infants
and from each of 22 infants treated with concentrate
B (neutralization titer, 1:1,1(0) were checked for the
presence of bovine milk immunoglobulins by the
Ouchterlony test and for neutralizing activity against
bovine rotavirus VlOO5, which is serologically
unrelated to human rotavirus [31]. Concentrate
B-treated infants had bovine immunoglobulins in
21 (48010) of the 44 stool samples examined and in
11 (25010) stool samples, neutralizing activities, with
a mean neutralization titer of 1:8 (mean of neutraliz-
ing stool samples only). Bovine immunoglobulins
were, however, undetectable in 110 stool samples
from control infants; only three (30,10) of these stool
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Figure 3. Immunodiffusion test (Ouchterlony) of stool
extracts. +, Concentrate-treated infants; -, control in-
fants; AS, rabbit antiserum to bovine IgGl; MIC, 1 mg
of milk immunoglobulin concentrate/ml; and HS, human
serum diluted 1:200.
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Figure 4. Immunoelectrophoresis of stool extracts. An-
tigen wells 41, 49, 42, and 50, from concentrate-treated
infants; well 6, from a control infant; antiserum troughs,
rabbit antiserum to bovine IgGl; A, B, and C, fragments
A, B, and C of bovine IgGl; and MIC, 1 mg of control
concentrate/ml. The anode is on the left.
samples showed neutralizing activity against bovine
rotavirus VI005.
Three hundred four stool samples from 43 infants
treated with the high-titered concentrate C prepara-
tion (neutralization titer, 1:6,(00) were studied, in-
cluding stool samples taken before and after treat-
ment. One hundred forty-two (47010) samples had
bovine immunoglobulins and 132 (43010) samples,
rotavirus Vl005-neutralizing activities, with a mean
neutralization titer of 1:48 (mean for neutralizing
stool samples only). There was a nearly perfect corre-
lation between the presence of bovine IgGl, as shown
by the immunodiffusion technique, and neutraliz-
ing activity. One hundred twenty-two stool samples
had both bovine IgGI and neutralizing activity, 12
had neutralizing activity without detectable IgGl
(3.9010, as in control infants, see above), and 19 had
IgGI but were not neutralizing. All but six of the
43 infants treated with concentrate C had at least
two neutralizing stool samples. From the known
amount of concentrate ingested by infants and the
measured neutralizing activity in the stool samples,
we estimated that "-'10010 of the orally administered
antiviral activity was recovered from stools after gas-
trointestinal passage.
Figure 5 shows the parallel appearance of bovine
immunoglobulins and virus-neutralizing activity in
stool samples from 43 infants treated with concen-
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Figure 5. Left, the appearance of bo-
vine immunoglobulins (black bars)and
virus-neutralizing activity (white bars)
in stool samples from concentrate
C-treated infants. The treatment
period is indicated by a horizontal
white bar. Right, the mean neutraliza-
tion titer (N1) of stool samples from
all concentrate C-treated infants in re-
lation to the treatment period.
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trate C. From the third treatment day until one day
after cessation of treatment, 79070 of all stool sam-
ples were positive for bovine IgGI, and 65070 neu-
tralized bovine rotavirus VlOO5, with a mean neu-
tralization titer of 1:34 for all stool samples (negative
stools included). Ninety-four percent and 67070 of the
stool samples that neutralized bovine rotavirus VlOO5
also neutralized simian rotavirus SA-ll and human
rotavirus Wa, respectively. An analysis of stool sam-
ples from individual patients revealed that, on aver-
age, infants excreted nonneutralizing stool samples
for 1.6days after the start of treatment, whereas neu-
tralizing stool samples were still observed, on aver-
age, 1.5 days after the end of treatment. From these
figures, we estimated that it took 1'\J1.5 days for the
concentrates to pass through an infant's digestive
tract. Cessation of excretion of virus correlated with
the appearance of neutralizing activity in 19 (75070)
of 25 analyzed infants (representative example is
shown in figure 6A), although this kinetic correla-
tion did not prove a causal relationship. In six (25070)
of 25 infants, rotavirus was still excreted, despite the
presence of neutralizing activity (representative ex-
ample is shown in figure 6B).
Treatment ofgastroenteritis. Hospitalized chil-
dren suffering from rotavirus diarrhea were treated
over three consecutive years with three different milk
immunoglobulin concentrates. In the first trial (win-
ter of 1982-1983), infants were given concentrate A,
which had a mean neutralization titer of 1:330 (for
a 10070 solution) against the four human rotavirus
serotypes. No significant positive effects were seen
in treated infants when compared with control in-
fants (table I). Concentrate B, with a mean neutraliz-
Figure 6. Excretion of virus mea-
sured as optical density (OD) in an
ELISA (black bars) and virus-
neutralizing activity (white bars) indi-
cated by the neutralization titer (N1)
in stool samples from two concentrate
C-treated infants. The treatment per-
iod is indicated by the white horizon-
tal bar. ., Stool samples containing
bovine IgO; and arrow,cutoff point for
rotavirus-positive ELISA values.
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Table 1. Treatment of rotavirus gastroenteritis with a bovine milk concentrate containing antibody to rotavirus.
Duration (days) of event after hospitalization
Diarrhea Excretion of virus
Study period Treatment* No. of infants Mean ± SE P Mean ± SE P
None 22 2.73 ± 0.43 } 3.91 ± 0.51 }
1982-1983 Concentrate A 23 3.52 ± 0.42 .16 4.04 ± 0.35 .75
None 24 2.29 ± 0.39} 3.58 ± 0.48}
1983-1984 Concentrate B 22 2.59 ± 0.36 .58 4.23 ± 0.39 .31
None 43 3.36 ± 0.33} 5.02 ± 0.29 }
1984-1986 Concentrate C 30 2.93 ± 0.25 .349 3.87 ± 0.28 .008
NOTE. The P values are based on the Ancova test with the covariable duration of diarrhea before hospitalization.
* Two grams of concentrate/kg of body weight per day was mixed into an appropriate dietary regimen; treatment started on
the second day of hospitalization.
ing titer of 1:1,100(for a 10070 solution) against hu-
man rotaviruses, was administered to children in a
second clinical trial (winter of 1983-1984). Again,
no difference was detected between treated and con-
trol infants (table 1).
In a third clinical trial (winters of 1984-1985 and
1985-1986), infants were treated with concentrate C,
with a mean neutralizing titer of 1:6,000 (for a 10070
solution) against human rotaviruses. This treatment
resulted in a decrease in the duration of excretion
of virus after hospitalization; the mean was 5.02 days
in control infants and 3.87 days in treated infants
(P = .008). Although a decease in the duration of
diarrhea was observed (2.93 days in treated infants
vs. 3.36 days in controls), this difference was not
statistically significant (table 1).
The clinical results correlated with the recovery
of antiviral activity from the stools. Infants treated
ineffectively with concentrate B (neutralization titer,
1:1,1(0) had neutralizing activity in only 250',10 of the
stool samples, with a mean titer of 1:8. Infants
treated successfully with concentrate C (neutraliza-
tion titer, 1:6,000) showed neutralizing activity in
43070 of the stool samples, with a mean titer of 1:48.
The strongest evidence for an effect was that a close
relationship was also found within the concentrate
C-treated group. Only infants with high levels of
neutralizing activity in stools (two or more stool sam-
ples with neutralization titers ~1 :20) showed a clini-
cal effect, compared with control infants (3.36 days
vs. 5.02 days for the duration of excretion of virus
and 2.54 days vs. 3.36 days for the duration of diar-
rhea; table 2). Infants with low levels of neutraliz-
ing activity in their stools were, however, clinically
indistinguishable from control infants (5.00 days vs.
5.02 days for excretion of virus and 3.13days vs. 3.36
days for diarrhea; table 2).
Toensure that patient randomization into the con-
Table 2. Clinical response of concentrate C-treated infants with high and low neutralizing activities in their stools.
Duration (days) of event after hospitalization
Diarrhea Excretion of virus
Neutralizing
Treatment group titer in stool No. of infants Mean SE Mean SE
Concentrate C Low 15 3.13 0.47 5.00 0.26
Concentrate C High 22 2.54 0.32 3.36 0.37
Control None 43 3.36 0.33 5.02 0.29
NOTE. For diarrhea, P values (as determined by the Ancova test) were .378 for infants with low neutralizing titers vs. high
neutralizing titers, .117 for infants with high neutralizing titers vs. controls, and .698 for infants with low neutralizing titers vs.
controls. For excretion of virus, P values (as determined by the Ancova test) were .007 for infants with low neutralizing titers vs.
high neutralizing titers, <.001 for infants with high neutralizing titers vs. controls, and .966 for infants with low neutralizing titers
vs. controls.
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trol or treatment group could not be a source of er-
ror for interpretation, we examined the following
criteria. No significant differences were found for
age or sex between the groups (table 3). The severity
of illness, as determined by the duration of diarrhea
before hospitalization and the necessity of ad-
ministering parenteral fluid, was also found to be
evenly distributed over the two groups of patients
(table 3). Finally, an inquiry into the socioeconomic
status of patients revealed no differences. In this
highly industrialized region of West Germany, with
a high population density (Bochum is situated near
the center of the Ruhr area), the majority of parents
have the social status of skilled or unskilled workers.
With regard to the problem of false-negative
results in rotavirus detection by ELISA, stool sam-
ples from the critical period of transition from
ELISA-positive to ELISA-negative values were in-
dependently checked by RNA gel electrophoresis or
by electron microscopy or by both techniques. We
disposed of the stool samples taken during these crit-
ical periods from 38 infants treated with concentrate
C. In 34 (89070) cases the first negative ELISA could
be confirmed by a negative result by RNA gel elec-
trophoresis and by electron microscopy. In four cases
the first but not the second ELISA-negative stool
samples turned out to be positive by RNA gel elec-
trophoresis; only one of these samples was also posi-
tive by electron microscopy. Despite being negative
by ELISA, all four samples were counted as posi-
tive for rotavirus in the evaluation of the clinical test.
No negative side effects were observed in the 75
infants who received the different concentrates in the
three study periods.
Discussion
In this report we have demonstrated that bovine milk
immunoglobulins with neutralizing-antibody activity
against four human rotavirus serotypes can be used
as a therapeutic agent to reduce the excretion time
of rotavirus in acute rotavirus gastroenteritis in in-
Hilpert et al.
fants. A basic requirement for successfully treating
this disease is the high-titer neutralizing activity of
the milk immunoglobulin concentrates because con-
centrates with a less-potent activity gave negative
results (table 1).The need for a high-titered antibody
preparation for therapy can also be deduced from
previous failures to treat rotavirus gastroenteritis with
preparations that showed prophylactic activity [24,
25]. Medium-titered concentrate B may, however,
also have some positive effect. A therapeutic study
with concentrate B, carried out at the Children's Hos-
pital of Philadelphia, resulted, as found in Bochum,
in nonsignificant differences between the mean num-
ber of diarrheal stools per day in treated infants as
opposed to control infants but in a significantly bet-
ter increase in body weight in the concentrate-treated
group (+ 5070 on day 4 of treatment) compared with
controls ( - 2070 on day 4, P < .001; H. F. Clark and
S. A. Plotkin, personal communication).
It is remarkable that orally administered heterol-
ogous antibodies can resist proteolytic degradation
during gastrointestinal passage without special pre-
cautions, such as encapsulation or addition of ant-
acid. Earlier reports from our group [37]have shown
that bovine milk antibodies to E. coli retained their
immunologic activity after gastrointestinal passage.
In vitro digestion of bovine milk concentrate con-
taining antibodies to rotavirus, as described in this
paper, shows that a substantial amount of activity
of neutralizing antibodies to rotavirus is still active
after pepsin and trypsin treatment. This outcome is
confirmed by our in vivo studies, in which quantita-
tive comparison of ingested and recovered activity
of antibody to rotavirus allowed us to conclude that
rvl00J0 of the antiviral activity survived gastrointes-
tinal passage. Similar results were reported by other
authors, who showed the survival of human serum
immunoglobulins after being orally administered to
low-birth-weight infants [38] and the conservation
of specific antitoxic activity of bovine milk immu-
noglobulins in in vitro and in vivo digestion trials
in rabbits [39]. Our results show that orally ad-
Table 3. Characteristics of the concentrate-treated and control groups for the study period 1984 -1986.
Sex ratio, Duration (days) of diar- No. who received
Treatment group No. of infants Mean age (months) male/female rhea before hospitalization perenteral fluid therapy
Concentrate C 30 6.9 20/10 2.02 7
Control 43 6.0 24/19 2.03 7
Bovine Milk Antibodies to Rotavirus
ministered antibodies can limit rotavirus replication,
even after the onset of clinical symptoms. One pos-
sible explanation may be that bovine antibodies neu-
tralize rotaviruses set free into the lumen of the
intestine by infected epithelial cells. Milk immuno-
globulins could thus limit, or even inhibit, further
spread of the viral infection to hitherto uninfected
epithelial cells or uninfected parts of the intestine.
We found appreciable amounts of neutralizing ac-
tivity against human rotaviruses in the stools of con-
centrate C-treated infants. Thus, treatment with milk
immunoglobulin concentrate may lower the infec-
tivity of rotavirus excreted into the stool. Unfortu-
nately, human rotaviruses are notoriously difficult
to cultivate in cell culture, and we could not there-
fore test this hypothesis experimentally. Neverthe-
less, this concentrate treatment could also have
beneficial effects in limiting the potential spread of
rotavirus infection in hospitals.
The decrease in the duration of diarrhea was in-
significant in this study, probably for the following
reasons. Because of the dietary treatment of both
groups, diarrhea was of shorter duration than was
excretion of virus (3.36 days of diarrhea vs. 5.02days
of excretion of virus in control infants). Hence, from
a statistical point of view, the diarrhea criterion is
not an uninfluenced, chance variable for evaluating
therapeutic efficacy, as is the case with excretion of
virus in control and concentrate-treated infants.
Moreover, in most cases, treatment with the concen-
trate could only be started on the second day of hos-
pitalization because of problems in obtaining paren-
tal consent to include their sick infant in the
concentrate-treated group. Finally, by our studies on
the kinetics of intestinal passage of milk immuno-
globulin concentrate, we know that it took about one
day to establish a milieu with neutralizing activity
in the intestine. Therefore, it is conceivable that con-
centrate treatment started too late to influence diar-
rheal symptoms. Omission of dietary treatment in
both groups may prolong diarrhea and thus increase
the chances of observing a significant effect of the
concentrate on diarrhea; however, this procedure is
ethically unacceptable for control infants. Wethere-
fore decided that for the next clinical tests, we would
begin treatment within 12 hr of hospitalization.
Nevertheless, it remains remarkable that in an
acute infection, viral replication can be influenced
therapeutically by passivelyacquired antibodies, even
after the onset of clinical illness.
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